← The Wire
PYXSNasdaq
Pyxis Oncology, Inc.
Pharmaceutical Preparations · DE · CIK 1782223
Pyxis Oncology develops novel antibody-drug conjugates targeting solid tumors, initially focusing on head and neck cancer
red 8-K · 90d
$112M
Market cap
$2.86
Last close
+3.3%
1D
+34.3%
5D
1.3M
Volume
Price · last 39 sessions+62.5%
May 4L $1.63 · H $2.86Jun 29
108
Total filings
Jun 15, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 15, 202610-Q10-QMay 14, 20268-KResults of OperationsMay 14, 2026DEFA14ADEFA14AApr 30, 2026DEF 14ADEF 14AApr 30, 20268-K/AExecutive ChangeApr 30, 202610-K10-KMar 23, 20268-KResults of Operations · Reg FD DisclosureMar 23, 20268-KCompany UpdateFeb 6, 20268-KReg FD Disclosure · Company UpdateDec 18, 202510-Q10-QNov 3, 20258-KResults of OperationsNov 3, 202510-Q10-QAug 14, 20258-KResults of OperationsAug 14, 20258-KCompany UpdateAug 4, 20258-KExecutive ChangeJul 3, 20258-KShareholder VoteJun 18, 202510-Q10-QMay 15, 20258-KResults of Operations · Reg FD DisclosureMay 15, 2025DEFA14ADEFA14AApr 29, 2025DEF 14ADEF 14AApr 29, 20258-KReg FD DisclosureMar 24, 202510-K10-KMar 18, 20258-KExecutive Change · Results of OperationsMar 18, 20258-KCompany UpdateFeb 26, 20258-KCompany UpdateFeb 4, 20258-KCompany UpdateDec 19, 20248-KReg FD DisclosureNov 20, 202410-Q10-QNov 12, 20248-KResults of OperationsNov 12, 20248-KShareholder VoteOct 23, 2024DEF 14ADEF 14ASep 25, 202410-Q10-QAug 14, 20248-KResults of OperationsAug 14, 20248-KShareholder VoteJun 12, 20248-KExecutive Change · Reg FD DisclosureJun 10, 202410-Q10-QMay 14, 20248-KResults of OperationsMay 14, 2024DEFA14ADEFA14AApr 26, 2024DEF 14ADEF 14AApr 26, 20248-KCompany UpdateMar 27, 20248-KCompany UpdateMar 27, 202410-K10-KMar 21, 20248-KResults of Operations · Reg FD DisclosureMar 21, 20248-KExecutive Change · Reg FD DisclosureMar 13, 2024SC 13GSC 13GMar 8, 20248-KMaterial Agreement · Equity IssuanceFeb 28, 2024SC 13GSC 13GJan 26, 20248-KExecutive ChangeNov 28, 202310-Q10-QNov 7, 20238-KResults of OperationsNov 7, 20238-K/ACompany UpdateOct 27, 20238-KExecutive Change · Acquisition / DispositionAug 23, 202310-Q10-QAug 11, 2023425425Aug 11, 20238-KResults of OperationsAug 11, 2023425425Aug 11, 20238-KCompany UpdateAug 11, 2023425425Jun 30, 20238-KExecutive ChangeJun 30, 20238-KShareholder VoteJun 13, 2023S-4FORM S-4Jun 8, 2023425425May 30, 2023425425May 25, 2023425425May 24, 2023425425May 24, 20238-KReg FD DisclosureMay 24, 2023425425May 24, 2023425425May 24, 20238-KExecutive Change · Material AgreementMay 24, 202310-Q10-QMay 11, 20238-KResults of OperationsMay 11, 202310-K/A10-K/AMay 10, 2023DEFA14ADEFA14AApr 28, 2023DEF 14ADEF 14AApr 28, 20238-KExecutive ChangeMar 28, 202310-K10-KMar 22, 20238-KExecutive Change · Results of OperationsMar 22, 20238-KReg FD DisclosureMar 16, 2023SC 13GSC 13GFeb 8, 2023
Insider Activity
In the 90 days to Apr 21, 2025: 1 sold $16K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 21, 2025 | Humphrey RachelDirector | Sell | 13,896 | $1.03 | $14K |
| Apr 17, 2025 | Humphrey RachelDirector | Sell | 200 | $0.97 | $194 |
| Apr 14, 2025 | Humphrey RachelDirector | Sell | 1,400 | $0.97 | $1K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance